دورية أكاديمية
أعرض في EDS

Treg-recruiting microspheres prevent inflammation in a murine model of dry eye disease.

التفاصيل البيبلوغرافية
العنوان: Treg-recruiting microspheres prevent inflammation in a murine model of dry eye disease.
المؤلفون: Ratay ML; Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA 15216, United States., Glowacki AJ; Department of Chemical Engineering, University of Pittsburgh, Pittsburgh, PA 15216, United States., Balmert SC; Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA 15216, United States., Acharya AP; Department of Chemical Engineering, University of Pittsburgh, Pittsburgh, PA 15216, United States., Polat J; Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States; Fox Center for Vision Restoration, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States., Andrews LP; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15260, United States., Fedorchak MV; Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA 15216, United States; Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States; Fox Center for Vision Restoration, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States., Schuman JS; Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States; Fox Center for Vision Restoration, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States., Vignali DAA; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15260, United States; Department of Tumor Microenvironment Center, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15232, United States., Little SR; Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA 15216, United States; Department of Chemical Engineering, University of Pittsburgh, Pittsburgh, PA 15216, United States; Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, United States; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15260, United States. Electronic address: srlittle@pitt.edu.
المصدر: Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2017 Jul 28; Vol. 258, pp. 208-217. Date of Electronic Publication: 2017 May 10.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Elsevier Science Publishers Country of Publication: Netherlands NLM ID: 8607908 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4995 (Electronic) Linking ISSN: 01683659 NLM ISO Abbreviation: J Control Release Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Amsterdam : Elsevier Science Publishers, 1984-
مواضيع طبية MeSH: Anti-Inflammatory Agents/*administration & dosage , Chemokine CCL22/*administration & dosage , Delayed-Action Preparations/*chemistry , Dry Eye Syndromes/*complications , Inflammation/*prevention & control , T-Lymphocytes, Regulatory/*drug effects, Animals ; Anti-Inflammatory Agents/therapeutic use ; Chemokine CCL22/therapeutic use ; Disease Models, Animal ; Drug Delivery Systems ; Dry Eye Syndromes/immunology ; Female ; Inflammation/immunology ; Mice, Inbred BALB C ; T-Lymphocytes, Regulatory/immunology
مستخلص: Dry eye disease (DED) is a common ocular disorder affecting millions of individuals worldwide. The pathology of DED involves the infiltration of CD4 + lymphocytes, leading to tear film instability and destructive inflammation. In the healthy steady state, a population of immunosuppressive T-cells called regulatory T-cells (Treg) regulates proliferation of immune cells that would otherwise lead to a disruption of immunological homeostasis. For this reason, it has been suggested that Tregs could restore the immunological imbalance in DED. To this end, one possible approach would be to recruit the body's own, endogenous Tregs in order to enrich them at the site of inflammation and tissue destruction. Previously, we have demonstrated a reduction of inflammation and disease symptoms in models of periodontitis corresponding to recruitment of endogenous Tregs, which was accomplished by local placement of controlled release systems that sustain a gradient of the chemokine CCL22, referred to here as Treg-recruiting microspheres. Given that DED is characterized by a pro-inflammatory environment resulting in local tissue destruction, we hypothesized that the controlled release of CCL22 could also recruit Tregs to the ocular surface potentially mediating inflammation and symptoms of DED. Indeed, data suggest that Treg-recruiting microspheres are capable of overcoming the immunological imbalance of Tregs and CD4 + IFN-γ + cells in the lacrimal gland. Administration of Treg-recruiting microspheres effectively mitigated the symptoms of DED as measured through a number of outcomes such as tear clearance, goblet cells density and corneal epithelial integrity, suggesting that recruitment of endogenous Treg can mitigate inflammation associated with DED.
(Copyright © 2017. Published by Elsevier B.V.)
References: Invest Ophthalmol Vis Sci. 2015 Nov;56(12):7545-50. (PMID: 26618646)
Biomaterials. 2005 Aug;26(24):5048-63. (PMID: 15769541)
Curr Opin Clin Nutr Metab Care. 2010 Sep;13(5):541-7. (PMID: 20657280)
Invest Ophthalmol Vis Sci. 2008 Dec;49(12):5434-40. (PMID: 18658093)
Hepatology. 1995 Jan;21(1):190-8. (PMID: 7806154)
Invest Ophthalmol Vis Sci. 2002 Aug;43(8):2609-14. (PMID: 12147592)
Invest Ophthalmol Vis Sci. 2014 May 06;55(5):2963-74. (PMID: 24722696)
Invest Ophthalmol Vis Sci. 2011 Aug 09;52(9):6279-85. (PMID: 21474767)
Mol Ther. 2015 Jan;23(1):139-46. (PMID: 25152016)
Front Immunol. 2012 Mar 21;3:51. (PMID: 22566933)
J Clin Invest. 2011 Aug;121(8):3024-8. (PMID: 21737880)
Invest Ophthalmol Vis Sci. 2014 Aug 19;55(9):5871-7. (PMID: 25139737)
Vet Sci. 2015 Apr 10;2(2):43-51. (PMID: 29061930)
J Immunol. 2009 Mar 1;182(5):2753-65. (PMID: 19234170)
Cornea. 2014 Jan;33(1):18-21. (PMID: 24240491)
Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5175-81. (PMID: 26244293)
Angew Chem Int Ed Engl. 2012 Oct 22;51(43):10800-3. (PMID: 23011773)
J Immunol. 2012 Feb 15;188(4):1742-50. (PMID: 22238462)
Invest Ophthalmol Vis Sci. 2004 Sep;45(9):3170-6. (PMID: 15326137)
Surv Ophthalmol. 2001 Mar;45 Suppl 2:S203-10. (PMID: 11587144)
Exp Eye Res. 2014 Aug;125:210-6. (PMID: 24983144)
Immunity. 2009 May;30(5):656-65. (PMID: 19464988)
Arch Ophthalmol. 2002 Mar;120(3):330-7. (PMID: 11879137)
Invest Ophthalmol Vis Sci. 2011 Apr 22;52(5):2627-33. (PMID: 21245405)
Eur J Immunol. 2001 Mar;31(3):812-22. (PMID: 11241286)
Invest Ophthalmol Vis Sci. 2011 Sep 21;52(10):7267-73. (PMID: 21849424)
Prog Retin Eye Res. 2012 May;31(3):271-85. (PMID: 22426080)
Ann Biomed Eng. 2015 Mar;43(3):593-602. (PMID: 25245220)
Invest Ophthalmol Vis Sci. 2010 Jun;51(6):3083-91. (PMID: 20130281)
Ophthalmology. 2006 Mar;113(3):363-372.e5. (PMID: 16458968)
Int Rev Immunol. 2013 Feb;32(1):19-41. (PMID: 23360156)
Cornea. 2011 Apr;30(4):379-87. (PMID: 21045640)
Ocul Surf. 2007 Apr;5(2):75-92. (PMID: 17508116)
J Immunol. 2015 Oct 1;195(7):3086-99. (PMID: 26324767)
J Bone Miner Res. 2015 Mar;30(3):412-22. (PMID: 25264308)
Cell. 2008 May 30;133(5):775-87. (PMID: 18510923)
Integr Biol (Camb). 2013 Mar;5(3):481-94. (PMID: 23392181)
Ocul Surf. 2014 Apr;12(2):87-99. (PMID: 24725321)
Arch Ophthalmol. 2012 Jan;130(1):90-100. (PMID: 22232476)
Eye (Lond). 2002 Nov;16(6):705-9. (PMID: 12439663)
Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18525-30. (PMID: 24167272)
PLoS One. 2009 Nov 20;4(11):e7848. (PMID: 19936238)
Nat Med. 2004 Sep;10(9):942-9. (PMID: 15322536)
Arch Ophthalmol. 2000 Nov;118(11):1489-96. (PMID: 11074805)
Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3802-7. (PMID: 19339740)
Cancer Immunol Immunother. 2010 Sep;59(9):1367-77. (PMID: 20480365)
Nat Immunol. 2002 Feb;3(2):135-42. (PMID: 11812990)
Invest Ophthalmol Vis Sci. 2006 Jan;47(1):133-9. (PMID: 16384954)
Exp Eye Res. 2013 Dec;117:118-25. (PMID: 24012834)
Adv Mater. 2012 Sep 11;24(35):4735-8. (PMID: 22821823)
J Invest Dermatol. 2015 Jun;135(6):1574-1580. (PMID: 25634358)
J Immunol. 2011 Oct 15;187(8):4170-7. (PMID: 21918194)
Front Immunol. 2014 Feb 11;5:46. (PMID: 24575095)
Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2171-6. (PMID: 20133862)
J Control Release. 2010 Sep 1;146(2):241-60. (PMID: 20493221)
Biomaterials. 2011 Jul;32(21):4903-13. (PMID: 21463892)
Invest Ophthalmol Vis Sci. 2008 Apr;49(4):1386-91. (PMID: 18385054)
J Immunol. 2009 Feb 1;182(3):1247-52. (PMID: 19155469)
Mucosal Immunol. 2014 Jan;7(1):38-45. (PMID: 23571503)
Eye Contact Lens. 2014 Jul;40(4):248-56. (PMID: 25390549)
J Clin Invest. 1990 Dec;86(6):1976-84. (PMID: 2254455)
PLoS One. 2013 Nov 04;8(11):e78508. (PMID: 24223818)
Exp Eye Res. 2006 May;82(5):885-98. (PMID: 16309672)
Invest Ophthalmol Vis Sci. 2002 Mar;43(3):632-8. (PMID: 11867577)
Eye (Lond). 2015 May;29(5):656-61. (PMID: 25744443)
Trends Immunol. 2008 Sep;29(9):429-35. (PMID: 18676178)
Mucosal Immunol. 2010 Sep;3(5):425-42. (PMID: 20485329)
Adv Drug Deliv Rev. 1997 Oct 13;28(1):5-24. (PMID: 10837562)
J Immunol. 2005 May 1;174(9):5620-9. (PMID: 15843561)
Immunol Cell Biol. 2005 Aug;83(4):375-82. (PMID: 16033532)
معلومات مُعتمدة: TL1 TR000145 United States TR NCATS NIH HHS; TL1 TR001858 United States TR NCATS NIH HHS; R01 DK089125 United States DK NIDDK NIH HHS; P01 AI108545 United States AI NIAID NIH HHS; P30 EY008098 United States EY NEI NIH HHS
فهرسة مساهمة: Keywords: CCL22; Drug delivery; Dry eye disease; Treg-recruiting microspheres; Tregs
المشرفين على المادة: 0 (Anti-Inflammatory Agents)
0 (Chemokine CCL22)
0 (Delayed-Action Preparations)
تواريخ الأحداث: Date Created: 20170515 Date Completed: 20180329 Latest Revision: 20231110
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC7805562
DOI: 10.1016/j.jconrel.2017.05.007
PMID: 28501670
قاعدة البيانات: MEDLINE
الوصف
تدمد:1873-4995
DOI:10.1016/j.jconrel.2017.05.007